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ABSTRACT: Kinases represent one of the most intensively
pursued groups of targets in modern-day drug discovery. Often it
is desirable to achieve selective inhibition of the kinase of interest
over the remaining ∼500 kinases in the human kinome. This is
especially true when inhibitors are intended to be used to study the
biology of the target of interest. We present a pipeline of open-
source software that analyzes public domain data to repurpose
compounds that have been used in previous kinase inhibitor
development projects. We define the dual-specificity tyrosine-
regulated kinase 1A (DYRK1A) as the kinase of interest, and by
addition of a single methyl group to the chosen starting point we
remove glycogen synthase kinase β (GSK3β) and cyclin-dependent kinase (CDK) inhibition. Thus, in an efficient manner we
repurpose a GSK3β/CDK chemotype to deliver 8b, a highly selective DYRK1A inhibitor.
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In recent years clinical successes have demonstrated the largepotential of kinase inhibitors to become approved drugs.1
However, achieving the desired selectivity profile remains a
significant challenge. A number of general methods to gain
selectivity have been documented, such as targeting the
nonconserved, inactive DFG-out (Type II) conformation of
the kinase,2 allosteric-site directed (Type III) inhibition,3 or
compounds that access a nonconserved pocket behind the
gatekeeper residue (Type I1/2).4 Thus far, the majority of FDA-
approved kinase inhibitors are found to bind in a conventional
Type I, ATP competitive mode.
Kinase profiling data contains both on- and off-target data
for compounds often from the same chemical class, derived
from the same data source. Routine assessment of off-target
activity facilitates the design of a desired selectivity profile, in
order to minimize off-target-related side effects. With the
availability of large kinase screening panels, various large scale
sets of homogeneous screening data for many compounds
against many kinases have been reported. These include
significant kinase data sets from Anastassiadis et al.,5 Davis et
al.,2 and Metz et al.,6 as well as the screening data derived from
the Published Kinase Inhibitor Sets 1 and 2 (PKIS/PKIS2).7−9
Many of these compound sets are comprised of molecules in
the realms of drug-like space, originating from pharmaceutical
industry drug discovery programs. These compounds and
associated data provide opportunities for repurposing kinase
inhibitors for targets of current interest.
The ChEMBL database10 holds records for over 1.3 million
compounds, with around 10 million compound bioactivity
measurements derived from published structure−activity
relationship studies and compound library screening studies.
An effective data-mining strategy is essential to utilize this
information. The Konstanz Information Miner (KNIME) is an
open source data analytics platform that can be used to mine
ChEMBL using premade workflows.11 ChEMBL KNIME
nodes and the NN-Activity Pairs workflow were developed
by workers at ChEMBL-EBI to highlight the polypharmacol-
ogy profiles of similar compounds within a cluster (nearest
neighbors). Differences in the polypharmacology profiles of
nearest neighbors can be interrogated to identify chemical
transformations that lead to better selectivity. The principles of
the NN-Activity Pairs workflow is shown in Figure 1 (a
schematic of the workflow is available in Supporting
Information Figure SI-1).
In the case where the binding mode of the series is known,
the position of the chemical transformation that has led to an
improvement in selectivity can be valuable in the design of
selective inhibitors. We illustrate the value of this approach in
the context of a target of current interest, dual-specificity
tyrosine-regulated kinase 1A (DYRK1A). We successfully
remove two key off-targets by utilizing the KNIME workflow.
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DYRK1A is of interest for inhibitor development due to its
purported roles in the development and progression of
neurodegenerative disorders such as Alzheimer’s Disease
(AD),12 Huntington’s Disease (HD), and Parkinson’s Disease
(PD).13−16 The DYRK1A gene is located on the Down’s
syndrome critical region of chromosome 21, consequently,
individuals with Down’s syndrome express elevated levels of
DYRK1A protein.17 Microduplication of the DYRK1A gene
resulted in dysmorphic and intellectual features characteristic
of a Down’s syndrome phenotype, supporting the hypothesis
that DYRK1A represents a novel target for the treatment of
Down’s syndrome.18 Increased tau phosphorylation is
observed in trisomy19,20 and Down’s syndrome is associated
with early onset AD, underscoring a genetic link between
DYRK1A, AD, and Down’s syndrome.21−25
Several DYRK1A inhibitors have been developed and
summarized in recent reviews.12,26 Although many are reported
as potent DYRK1A inhibitors, the majority of inhibitors have
not had their kinome-wide selectivity profiles reported; those
that have inhibit other members of the CMGC group27 of
kinases. Given the lack of reported DYRK1A inhibitors
progressing into and beyond clinical trials, there remains a
need to develop high quality chemical matter which can be
used for detailed biological study.28 Investigation of neuro-
development or neurodegeneration requires a CNS penetrant
inhibitor, capable of exerting an on-target effect in vivo. Two of
the most advanced DYRK1A inhibitors so far published are
L4129 and EHT 5372,30 which exhibit good potency and
kinome-wide selectivity. However, both possess potent off-
target activity at other CMGC kinases. L41 inhibits CLKs and
GSK3β,29 a kinase for which DYRK1A serves as a priming
kinase, and which regulates many of the same signaling
pathways as DYRK1A.31 Another CMGC kinase family that is
often inhibited by DYRK1A inhibitors is the cyclin-dependent
kinases (CDKs).32 Despite the availability of structural data, it
has been difficult to gain DYRK1A selectivity against CLKs,
GSK3β, and the CDKs, while optimizing DYRK1A inhibitory
activity (Figure 2).
■ RESULTS AND DISCUSSION
Data Mining Identified a Pyrazolo[1,5-b]pyridazine
Starting Point. Inspection of publicly available kinase
profiling data led to the identification of a cluster of kinase
inhibitors based on the pyrazolo[1,5-b]pyridazine core with
the potential to become a novel and drug-like DYRK1A
template.7−9 The pyrazolo[1,5-b]pyridazines were attractive
starting points in terms of drug-like properties, DYRK1A
binding affinity and kinome-wide selectivity. However, the
series originated from former GSK3β33 and CDK inhibitor
programs.34 Selectively removing inhibition of these two
kinases, while maintaining DYRK1A binding affinity and the
overall kinome-wide selectivity profile, was envisaged as a way
to afford a selective DYRK1A tool compound.
The NN-Activity Pairs KNIME workflow was used to mine
ChEMBL to highlight the polypharmacology profiles of nearest
neighbors. Inspection of the Kinase Activity Profile histogram
(Supporting Information, Figure SI-2) for the pyrazolo[1,5-
b]pyridazines revealed a number of matched-molecular pairs
(MMPs) and chemical transformations that led to significant
decreases in inhibitory activity against GSK3β and CDK2
(Figure 3).
Chemistry. An advantage of using publicly available
profiling data as a starting point for inhibitor discovery is
that information regarding synthetic routes has usually already
been published. Following the published procedure,33,34 the
aminated pyridazine 2 was formed in excellent yield after
reaction of pyridazine 1 with hydroxylamine-O-sulfonic acid
(HOSA). Subsequent [3 + 2] cycloaddition between 2 and 3-
butyne-2-one afforded the pyrazolo[1,5-b]pyridazine 3 in
average yield. DMF/DMA condensation furnished the
corresponding enamine 4 in excellent yield. Conversion of 4
to the corresponding pyrimidine was slow under conventional
heating at elevated temperatures, taking up to 48 h for the
formation of the desired product to occur (Scheme 1).
One disadvantage of the literature synthesis was that the
preparation of each analogue required the respective phenyl
guanidine to be synthesized first and in most cases the
synthesis of the phenyl guanidine was low yielding. Phenyl
guanidines were prepared using concentrated nitric acid and
cyanamide from the corresponding aniline (Scheme 2).33,34
Figure 1. Principles of workflow used to mine kinase profiling data.
The workflow was implemented in KNIME using the “NN-Activity
Pairs” workflow to mine ChEMBL.
Figure 2. Known DYRK1A inhibitors that also inhibit CMGC
kinases, including GSK3s and CDKs.
Figure 3. Activity cliffs identified rapidly from NN-Activity Pairs
KNIME workflow. Data from ChEMBL.10
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In an effort to improve the versatility of the synthesis, the
chloropyrimidine intermediate 5 was prepared. Nucleophilic
aromatic substitution with a range of nucleophiles was then
possible. Scale-up of 5 was completed in high yield from 4
(Scheme 3).
Two approaches were taken to install the N-methyl
substituent onto the aminopyrimidine. Nucleophilic aromatic
substitution of 5 with N-methylaniline afforded 6b in 44%
yield. Alternatively, N-methylation with sodium hydride and
iodomethane was carried out on late-stage analogues, 8a and
10a to access 8b and 10b, respectively (Scheme 4).
Inhibitor Optimization. The MMPs with the most
complete data set were 6a and 6b (Figure 3). The data
suggested that N-methylation of the aminopyrimidine N-H
reduced the inhibitory activity at both GSK3β and CDK2 of
the pyrazolo[1,5-b]pyridazine series by 2 log units. Pyrazolo-
[1,5-b]pyridazine analogues that were inactive against GSK3β
and CDKs were of great interest as DYRK1A inhibitors. N-
methylation was an attractive strategy to pursue for gaining
selectivity as the number of hydrogen-bond donors in the
series was reduced simultaneously, which could improve
permeability and CNS penetration of the series.
To confirm that N-methylation afforded selectivity against
the original series off-targets, GSK3β and CDK2, 6a and 6b
were profiled in a radiometric kinase assay (33PanQinase
Activity Assay) provided by Proqinase GMBH. The assay
measured the kinase activity of DYRK1A, GSK3β, and CDK2
in the presence and absence of inhibitors. Gratifyingly, the
selectivity profile predicted in KNIME was confirmed
experimentally, with 6b displaying selective inhibition of
DYRK1A, whereas 6a inhibited all three CMGC kinases
(Table 1).
Several pyrazolo[1,5-b]pyridazines were profiled against
DYRK1A in a binding-displacement assay (Table 2). In
general, analogues possessing meta-substituents on the aniline
ring exhibited stronger binding affinity for DYRK1A. Both
electron-donating (8a and 10a) and electron-withdrawing
(11a) substituents were well-tolerated in the meta-position.
Analogues with ortho and para substituents on the aniline ring
exhibited weaker DYRK1A binding affinity7a and 9a
exhibited approximately 10-fold weaker binding affinity than
meta analogues 8a and 10a, while 12a displayed 20-fold weaker
binding affinity for DYRK1A than meta analogue 11a.
Ortho and para-substituted analogues were deprioritized as
they possessed weaker DYRK1A binding affinity. The N-
methylated matched pairs of 6a, 8a, and 10a were synthesized
and assayed for DYRK1A binding affinity (Table 3).
Despite a reduction in DYRK1A binding affinity by more
than 5-fold for all N-methylated MMPs, the incorporation of
an N-methyl group was tolerated surprisingly well in DYRK1A.
8b and 10b both maintained high levels of DYRK1A binding
affinity (IC50 < 100 nM). The binding affinities of MMPs 8a
and 8b were confirmed by surface plasmon resonance (SPR)
measurements, which gave KD ± SEM values of 52 ± 4.5 nM
for 8b and 8.9 ± 2.1 nM for 8a (both n = 2), in good
agreement with the binding displacement assay (sensograms
are available in Supporting Information Figure SI-3).
The broader kinome selectivity of 8b was determined by the
KINOMEscan assay panel (DiscoverX). Percentage inhibition
data for CMGC kinases regularly inhibited by DYRK1A
inhibitors reported in the literature are summarized in Table 4
(the full data set is available in the Supporting Information).
8b exhibited good kinome-wide selectivity, with a Selectivity
Score (S-Score (40)) of 0.01. The successful removal of CDK2
Scheme 1a
aReagents and conditions: (i) hydroxylamine-O-sulfonic acid,
KHCO3, KI, H2O, 70 °C, 1.5 h, 94%; (ii) 3-butyne-2-one, KOH,
CH2Cl2, rt, 16 h, 60%; (iii) DMF-DMA, 100 °C, 16 h, 91%; (iv)
phenyl guanidines, 2-methoxyethanol, 110 °C, 16-48 h, 13−37%.
Scheme 2a
aReagents and conditions: (i) cyanamide (50 wt % in H2O), HNO3,
EtOH, 100 °C, 16-48 h, 35-62%.
Scheme 3a
aReagents and conditions: (i) urea, sodium, 140 °C, 10 min, 91%; (ii)
phosphorus(V)oxychloride, 110 °C, 3 h, 92%; (iii) conditions A:
anilines, 2-propanol, 150 °C, 2−16 h, 4−44%; conditions B: anilines,
2-propanol, 150 °C, 15−20 min, microwave, 43−60%.
Scheme 4a
aReagents and conditions: (i) sodium hydride, iodomethane, DMF,
rt, 2 h.
Table 1. CMGC Selectivity of 6a and 6b at 1 μM
Compound DYRK1Aa GSK3βa CDK2a
6a 97 76 98
6b 79 13 33
a% inhibition in 33PanQinase Activity Assay (n = 1).
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and GSK3β activity with the addition of the N-methyl group
was consistent with previous results, and selectivity against
DYRK1B, DYRK2, and CLK3 was also observed. The intrinsic
solubility of 8b was determined by the “shaking flask” method
in PBS buffer at pH 6.8.35 8b was also profiled for metabolic
stability (HLM, RLM). These results are displayed in Table 5.
8b exhibited a high rate of metabolic turnover in rat liver
microsomes, which would need to be taken into consideration
for rodent in vivo studies. The solubility of 8b was not optimal
but was comparable to other DYRK1A tool compounds
currently in use. Given the favorable selectivity profile and
strong binding affinity for DYRK1A, 8b was profiled in a
MDCK-MDR1 assay to assess whether there were any P-gp or
permeability issues with the series (Table 6).
The high CNS MPO score36 calculated for 8b correlated
with good levels of permeability and low P-gp efflux, indicating
that 8b, and analogues derived from the pyrazolo[1,5-
b]pyridazine series, stand a good chance of delivering
compounds capable of penetrating the blood−brain barrier
(BBB) and exerting an on-target effect in vivo.
The cocrystal structure of 6b bound to DYRK1A (PDB
6S1I) shows that despite possessing an N-methyl group close
to the hinge of DYRK1A, 6b is able to adopt a Type I binding
mode (Figure 4).
6b bound in a monodentate fashion to the hinge of
DYRK1A. The pyridine-type nitrogen of the pyrazolo portion
of the pyrazolo[1,5-b]pyridazine motif supports a long-range
water network at the back of the kinase pocket. The
nonbridging nitrogen belonging to the pyridazine portion of
the pyrazolo[1,5-b]pyridazine motif serves as a hydrogen-bond
acceptor (HBA) to the catalytic lysine (Lys188), further
stabilizing 6b in the ATP-site. The hinge-binding motif,
bearing an N-methyl substituent, appears to occupy a small
lipophilic pocket present at the hinge of DYRK1A.
6b and 8b differ only by the addition of a meta-methyl group
to the phenyl moiety in 8b, and therefore the crystal structure
with 6b serves as a good model for the binding of 8b. The lack
of literature precedent for the hinge-binding motif and the
Table 2. DYRK1A Binding Affinity of Pyrazolo[1,5-
b]pyridazines
a16-point IC50 (nM) in TR-FRET-based ligand-binding displacement
assay (n = 1).
Table 3. DYRK1A Binding Affinity of N-Methylated
Pyrazolo[1,5-b]pyridazines
a16-point IC50 (nM) in TR-FRET-based ligand-binding displacement
assay (n = 1).
Table 4. KINOMEscan Selectivity Profiling of 8b
Kinase Compound 8b
DYRK1A 65
DYRK1B 0
DYRK2 19
CLK1 59
CLK2 59
CLK3 6
CDK2 12
GSK3β 4
S Score (40) 0.01
a% inhibition at 1 μM inhibitor concentration determined in
competition binding assay (DiscoverX, n = 1).
Table 5. Metabolic Stability and Solubility of 8ba
Compound HLM RLM Solubility
8b 75.0 ± 3.1 805.3 ± 21.6 0.01
aHLM and RLM (μL/min/mg) determinations mean of n = 2. HLM
= human liver microsomes; RLM = rat liver microsomes;
thermodynamic solubility data (mg/mL) derived from single
experiment at pH 6.8.
Table 6. MDCK-MDR1 Permeability of 8b
Mean Papp (10
−6 cms−1)b
Compound
CNS
MPOa
score
Direction =
A2B
Direction =
B2A
Efflux Ratio (Mean
Papp B2A/Mean Papp
A2B)b
8b 4.8 20.9 ± 0.10 20.1 ± 0.90 0.96
aCNS MPO score calculated using CNS MPO KNIME workflow
with ChemAxon nodes. bData generated by Cyprotex in MDCK-
MDR1 assay. Permeability coefficient (Papp) calculated across cells in
direction: A2B (Apical to Basolateral) and B2A (Basolateral to
Apical). Determinations ± standard deviation (mean of n = 2).
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high-degree of kinome selectivity exhibited by 8b (S-Score
(40) = 0.01) suggest that this pocket may not be present in the
vast majority of other kinases. Targeting this pocket appears to
be a valid approach to gaining selectivity for DYRK1A.
■ CONCLUSION
While structure-based drug design (SBDD) is a proven
method for designing selective inhibitors, it remains the case
that often chemical modifications that yield selectivity are
found serendipitously and the rationale for compound
selectivity can remain unknown. Profiling data already in the
public domain can serve as a repository for chemical
transformations that can lead to improved selectivity. Data
mining tools such as KNIME can be utilized to extract this
information from open-source databases. The method
presented here can enable the design of kinase inhibitors
with improved selectivity versus off-targets. This strategy serves
as a complementary method to SBDD, helping to rationalize
compound selectivity.
The example of DYRK1A, presented here, shows that a
chemical modification, which may have been overlooked if
ligand data was not already available, can lead to more
selectivity against off-targets. A scaffold which was originally
developed as a CDK2/4/GSK3β inhibitor has been
repurposed into a selective DYRK1A inhibitor using a
chemoinformatics approach. Favorable selectivity against
DYRK1B and CLK3 has also been achieved in an efficient
manner. This novel class of DYRK1A inhibitors can serve as a
basis for future design of CNS-penetrant in vivo optimized
molecules.
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